Cancer Stem Cell News Volume 10.05 | Feb 10 2021







2021-02-10 | CSCN 10.05


Cancer Stem Cell News by STEMCELL Technologies
Vol. 10.05 – 10 February, 2021
TOP STORY

Targeting Cancer Stem Cells with a Pan-BCL-2 Inhibitor in Pre-Clinical and Clinical Settings in Patients with Gastroesophageal Carcinoma

Extensive pre-clinical studies in vitro and in vivo were carried out to establish the mechanism action of AT101 on targeting CSCs and antiapoptotic proteins.
[Gut]

Abstract

Watch the webinar where Dr. Suzan Imren discusses factors affecting the balance between HSC self-renewal and leukemic transformation
PUBLICATIONSRanked by the impact factor of the journal

Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma

Treatment of glioma cells with the dopamine receptor antagonist quetiapine reduced glioma cell self-renewal in vitro and combined treatment of mice with quetiapine and radiation prolonged the survival of glioma-bearing mice.
[JNCI-Journal of the National Cancer institute]

AbstractPress Release

Control of Replication Stress and Mitosis in Colorectal Cancer Stem Cells through the Interplay of PARP1, MRE11 and RAD51

Researchers showed that the replication stress response was efficient in primary CSCs from colorectal cancer, and described unique roles for PARP1 and MRE11/RAD51.
[Cell Death & Differentiation]

Full Article

Targeting the Sonic Hedgehog Pathway to Suppress the Expression of the Cancer Stem Cell (CSC)—Related Transcription Factors and CSC-Driven Thyroid Tumor Growth

Scientists report that inhibition of the sonic hedgehog pathway by Gli1 siRNA or by cyclopamine and GANT61 reduced B lymphoma Mo-MLV insertion region 1 homolog an SRY-Box Transcription Factor 2 expression in SW1736 and KAT-18 cells, two anaplastic thyroid cancer cell lines.
[Cancers]

Full Article

PPARα-Selective Antagonist GW6471 Inhibits Cell Growth in Breast Cancer Stem Cells Inducing Energy Imbalance and Metabolic Stress

The authors isolated and characterized breast CSCs from a triple-negative breast cancer cell line, MDA-MB-231. The obtained mammospheres were then treated with the specific PPARα antagonist GW6471, after which, glucose, lipid metabolism, and invasiveness were analyzed.
[Biomedicines]

Full Article

Circulating Prostate Cancer Cells Have Differential Resistance to Fluid Shear Stress-Induced Cell Death

Researchers explored how prostate circulating tumor cells could resist cell death in response to forces of >1,000 dyn/cm2. The DU145, PC3, and LNCaP human prostate cancer cell lines were used to represent cells of different metastatic origins.
[Journal of Cell Science]

AbstractFull Article

Radiation Response of Cervical Cancer Stem Cells Is Associated with Pretreatment Proportion of These Cells and Physical Status of HPV DNA

Scientists evaluated the association of radiation response of cervical CSCs with clinical and morphological parameters of disease and features of human papillomavirus (HPV) infection.
[International Journal of Molecular Sciences]

Full Article

IL-6 and IL-8, Secreted by Myofibroblasts in the Tumor Microenvironment, Activate HES1 to Expand the Cancer Stem Cell Population in Early Colorectal Tumor

Researchers investigated the CSC‐promoting effect of factors released from myofibroblasts into the microenvironment of early colorectal cancer tumors and its molecular mechanism.
[Molecular Carcinogenesis]

Abstract
Resources for Your T Cell Therapy Research
REVIEWS

Linking EMT Programmes to Normal and Neoplastic Epithelial Stem Cells

The authors outline the instances where aspects of an epithelial–mesenchymal transition (EMT) have been implicated in normal and neoplastic epithelial stem cells and consider the involvement of this programme during tissue regeneration and repair.
[Nature Reviews Cancer]

Abstract

Portrait of Cancer Stem Cells on Colorectal Cancer: Molecular Biomarkers, Signaling Pathways and miRNAome

Investigators summarize the epigenetic findings linked to miRNAome in the maintenance and regulation of colorectal cancer (CRC) stem cells (CCSCs), including their relationships with different signaling pathways, which should help to identify specific diagnostic, prognostic, and predictive biomarkers for CRC, but also develop innovative CCSCs-targeted therapies.
[International Journal of Molecular Sciences]

Full Article
INDUSTRY AND POLICY NEWS

Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors

Apollomics, Inc. and Edison Oncology Holding Corp., announced that Apollomics has been granted worldwide rights, excluding China, Hong Kong and Taiwan, for the development and commercialization of EO1001. EO1001 is a protein tyrosine kinase inhibitor that has demonstrated irreversible inhibition of EGFR, HER2 and HER4 as a single agent.
[Apollomics, Inc.]

Press Release

Lee’s Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer

China Oncology Focus Limited (COF) an affiliate of Lee’s Pharmaceutical Holdings Limited, and Sorrento Therapeutics, Inc. announced that its anti-PD-L1 antibody, socazolimab, licensed from Sorrento to COF for the greater China territory, has been granted breakthrough therapy designation by the China National Medical Products Administration to treat recurrent or metastatic cervical cancer.
[Lee’s Pharmaceutical]

Press Release
FEATURED EVENT

The 3rd UK Cellular Microbiology Network

March 1 – 2, 2021
Virtual

> See All Events

JOB OPPORTUNITIES

Postdoctoral Positions – Hematopoiesis, Leukemia, Cancer, Human Pluripotent Stem Cells

Icahn School of Medicine at Mount Sinai – New York, New York, United States

Postdoctoral Researcher – Mesenchymal Niche in Leukemia

Karolinska Institutet – Flemingsberg, Sweden

Postdoctoral Fellowship – Human Cancers

Memorial Sloan Kettering Cancer Center – New York, New York, United States

Medical Scientist – Breast Cancer

Gilead Sciences, Inc. – London, England, United Kingdom

Assistant / Associate Professor – Brain Tumor

University of Utah – Salt Lake City, Utah, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Cancer Stem Cell News Twitter


0
Share